Company intelligence / Profile preview
Pharmazz, Inc.
Willowbrook, Illinois, USApharmazz.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Pharmazz has brought its lead product Lyfaquin® (centhaquine) from discovery to market approval in India as a resuscitative agent for hypovolemic shock. Clinical data show a significant reduction in mortality. Sovateltide has shown promise as an endothelin B receptor agonist for acute ischemic stroke and other CNS disorders, with late-stage trials ongoing. The company maintains a robust pipeline targeting critical care indications.
- Therapeutic areas
- CardiovascularNeurologyInfectious Diseases
- Modalities
- Small molecules (e.g., centhaquine)Synthetic peptides (e.g., sovateltide)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Sun Pharma – investment up to $15M and Indian marketing rights to sovateltide/Tyvalzi™Dr. Reddy's Laboratories – Indian marketing rights to centhaquine/Lyfaquin®
Beyond the preview
Go deeper on Pharmazz, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmazz, Inc..